Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Post by Saaweeeetdreamson Feb 11, 2021 8:02am
203 Views
Post# 32535239

Scenarios

Scenarios

I believe we have a few scenarios to look at:

1. Aristotle will be launched any day as we have expanded the testing facilities and can do both Covid testing and Cancer testing at the same time. 

2. Aristotle will be launched at the very end of Q1 as we don't need the sales as covid testing is through the roof and they are currently extremely busy. Or as Covid testing slows down Cancer testing begins. No need to do both tests at the same time, spread the sales out to show steady growth. 

3. Aristotle will be launched at the very end of Q1 so they don't need to report any sales or no sales of Aristotle for 5-6 more months when Q2 is reported. 

4. Aristotle isn't launched in Q1


as investors we need to ask ourselves are you buying or selling because my thesis is........

<< Previous
Bullboard Posts
Next >>